Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Clinical trial NCT07186621 · RECRUITING

Trial details

NCT number: NCT07186621
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)Radiotherapy, Adjuvant Immune Checkpoint Inhibitor TACE Narrow Margin

Start date: 2025-07-10
Primary completion: 2027-07-09
Enrollment: 286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.